Login to Your Account



Clinic Roundup


Wednesday, February 15, 2012
• Dynavax Technologies Corp., of Berkeley, Calif., published data from a pivotal Phase III trial of Heplisav (HBV-10) in Vaccine. The data showed that a short, two-dose regimen of Heplisav over one month was well tolerated and superior to a three-dose regimen of hepatitis B vaccine over six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription